Hyperleukocytosis is a hematologic crisis caused by excessive proliferation of leuke-mic cells and has a relatively high early mortality due to a series of severe complications. Therefore, prompt and effective intervention is required. Leukapheresis performed using apheresis equipment to separate leukocytes from peripheral blood, at the same time returns autologous plasma, platelets and erythrocytes to the patient, is applied clinically for the treatment of hyperleu-kocytosis. Leukapheresis not only removes excessive leukocytes rapidly and corrects metabolic abnormalities but also alleviates the symptoms of leukostasis. In addition, the procedure of leukapheresis is generally well tolerated. Leukapheresis has become one of the most imperative adjuvant therapies to treat hyperleukocytosis, especially in the patient who was not inappropriate to cytoreduce with Ara-C or hydroxyurea. In this review, we present the background of leukapheresis development and highlight its clinical application in hyperleukocytic leukemia patients.
CITATION STYLE
Zhang, D., Zhu, Y., Jin, Y., Kaweme, N. M., & Dong, Y. (2021). Leukapheresis and hyperleukocytosis, past and future. International Journal of General Medicine. Dove Medical Press Ltd. https://doi.org/10.2147/IJGM.S321787
Mendeley helps you to discover research relevant for your work.